Article Sidebar
Views PDF: 132
INITIAL ASSESSMENT OF TREATMENT RESULTS FOR STAGE II, III SMALL CELL LUNG CANCER BY CONCURRENT CHEMORADIOTHERAPY AT THE NATIONAL LUNG HOSPITAL IN 2016-2020
Main Article Content
Abstract
Initial assessment of treatment results for stage II, III small cell lung cancer by concurrent chemoradiotherapy at the National Lung Hospital in 2016-2020. Subjects and methods: Observation of an uncontrolled retrospective clinical trial, we enrolled 71 patients with stage II, III small cell lung cancer to be recieved concurrent chemoradiotherapy with carboplatin and etoposide at the oncology department at National Lung Hospital from January 1, 2016 to December 31, 2020. Results: Median age 58.79±9.26, male/female ratio 34/1, performance status (PS)=0 (50/71, 70.42%), PS=1 (21/71, 29.58%), mainly TNM stage III (69/71, 97.18%) with IIIB (36/71, 50.70%) and IIIC (28/71, 39.44%). Complete response (12/71, 16.90%), partial response (45/71, 63.38%), overall response rate (57/71, 80.28%), stable disease (3/71, 4.23%, progressive disease (11/71, 15.49%). The median follow-up period was 32 months, median progression-free survival (PFS) was 16.4 months and median overall survival (OS) was 25 months, OS was affected by some factors such as age, PS. Acute hematological toxicity grade 3, 4 and 5 accounted for a fairly high rate ( 25/71, 35.21%). Non-hematological toxicity rates were very low, mainly grade 1 and grade 2, above grade 3 pneumonia (3/71, 4.23%), fever with leukopenia (5/71, 7.05%). Initial results of treatment of stage II, III small cell lung cancer by chemoradiotherapy was high efficiency and safety.
Article Details
Keywords
Concurrent chemoradiotherapy, small cell lung cancer
References
2. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20 (14):3054-3060. doi:10.1200/JCO.2002.12.071
3. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116-1125. doi:10.1016/S1470-2045(17)30318-2
4. Halvorsen TO, Sundstrøm S, Fløtten Ø, et al. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncol. 2016;55(11):1349-1354. doi:10.1080/0284186X.2016.1201216
5. Võ Văn Sơn. Nghiên cứu áp dụng phác đồ kết hợp hóa - xạ trị ung thư phổi tế bào nhỏ và đánh giá kết quả điều trị. Trường Đại Học Y Hà Nôi, Luận án tiến sỹ Y Học. Published online 2009:10-202.
6. Lê Văn Giao và cộng sự. Nghiên cứu kết quả điều trị ung thư phổi tế bào nhỏ bằng hóa xạ trị phối hợp tại Bệnh Viện Đa khoa Tỉnh Thanh Hóa. Tạp chí y học thực hành, (1066). Published online 2018:26-28.
7. Grønberg BH, Killingberg KT, Fløtten Ø, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology. 2021; 22(3):321-331. doi:10.1016/S1470-2045 (20)30742-7
8. Damhuis R, Widder J, Senan S. Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. Clin Oncol (R Coll Radiol). 2018;30(1):17-22. doi:10.1016/j.clon.2017.10.008